Mason Slaine, president and chief executive officer of IHI, reportedly welcomed the merger.
Press releases indicated that IHI's activities, including brand names Micropatent, Aureka, MDC, and Liquent, would integrate seamlessly with Thomson Scientific & Healthcare's other businesses in areas of intellectual property and drug development workflow solutions.